One platform. Compounding optionality.
Islet Sciences is a pharmaceutical platform company built around a proprietary biphasic drug delivery technology — designed to support multiple differentiated products across multiple therapeutic categories and multiple licensing transactions.
Value Architecture
How one platform creates compounding value.
Platform Technology
Multiple Molecules
Multiple Therapeutic Categories
Multiple Development Programs
Multiple Licensing Transactions
Recurring Royalty Streams
Portfolio Engine
Biphasic Drug Delivery Platform
Drug Candidate #1
Drug Candidate #2
Drug Candidate #3
Drug Candidate #4
Multiple Commercial Products
Long-Term Value Creation
Investment Pillars
Why the platform thesis matters.
Proprietary Platform Patent
US Patent 10,940,159 B2 — composition and method protection for biphasic IR / DR delivery.
Drug Delivery Innovation
An architecture purpose-built for the commercial challenge of short half-life pharmaceuticals.
Multi-Product Optionality
Applicable across multiple compounds, classes, and therapeutic categories — not a single-drug bet.
Licensing-Centric Model
Value created through non-dilutive licensing, milestones, and royalty structures.
Global Pharmaceutical Markets
Exposure to large, established therapeutic categories worldwide.
Scalable Monetization
Same platform, repeatable transactions — designed for compounding optionality.
Investor Relations